Menu Close

Trending

Data backs AZ’s Wilson disease drug, but with a question mark
Fujifilm acquires AI tech to improve fertility treatment
Sarepta shares yo-yo as FDA places hold on Duchenne trial
New countries stockpile antiviral TPOXX as monkeypox outbreak continues
Biogen and Happify partner on digital support for MS patients

Cibinqo

Human skin macro photo

News/ News/ Sales and Marketing

Leo puts target on Dupixent in US as FDA clears tralokinumab

, , , , , , , , , , , , , 0 Comment

Sanofi and Regeneron have another challenger to their big-selling drug Dupixent for atopic dermatitis, now that the FDA

X
Leo puts target on Dupixent in US as FDA clears tralokinumab
https://pharmaphorum.com/news/leo-puts-target-on-dupixent-in-us-as-fda-clears-tralokinumab/
Pfizer_Logo_Color_RGB_APPROVED

Market Access/ News/ News

Pfizer gets first approval, in UK, for Xeljanz follow-up Cibinqo

, , , , , , , 0 Comment

Pfizer has claimed its first regulatory approval worldwide for Cibinqo, its JAK inhibitor for atopic dermatitis, from the

X
Pfizer gets first approval, in UK, for Xeljanz follow-up Cibinqo
https://pharmaphorum.com/news/pfizer-gets-first-approval-in-uk-for-xeljanz-follow-up-cibinqo/

Login

CONTINUE TO SITE >
X
Close in 10 seconds